HC Wainwright initiated coverage on shares of PDS Biotechnology (NASDAQ:PDSB) in a report issued on Tuesday, FlyOnTheWall reports. The brokerage issued a buy rating and a $7.00 target price on the stock.

Separately, Chardan Capital began coverage on shares of PDS Biotechnology in a research report on Wednesday, October 23rd. They issued a buy rating and a $10.00 price target for the company.

Shares of PDSB opened at $2.92 on Tuesday. PDS Biotechnology has a 1-year low of $2.80 and a 1-year high of $17.00. The firm has a market capitalization of $15.53 million, a P/E ratio of -0.16 and a beta of 2.38. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.35 and a quick ratio of 5.35.

PDS Biotechnology (NASDAQ:PDSB) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.28). As a group, sell-side analysts predict that PDS Biotechnology will post -1.22 earnings per share for the current fiscal year.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical stage immuno-oncology company, develops multifunctional immunotherapeutic products. The company develops products to treat early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers.

Further Reading: Understanding Market Liquidity

Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.